Skip to main content

Table 1 Summary of Simulations: Variables and levels

From: The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models

Variable Levels simulated
Vaccination age for fitting databases EPI cohort 6, 10, 14 weeks
  5-17 month cohort all children ages between 5-17 months first dose, and for third dose 8-20 months
Vaccination age in predictions databases EPI schedule 6, 10, 14 weeks
  Extended routine vaccination schedule : 6, 7.5 and 9 months
  Boosting is 18 months post third dose (EPI 21 months, extended routine 27 months)
Model variants [11] 1) R0000 Base model
  2) R0068 Heterogeneity in transmission: within-host variability
  3) R0131 Immunity decay in effective cumulative exposure
  4) R0132 Immunity decay in immune proxies
  5) R0133 Immunity decay in both immune proxies and effective cumulative exposure
  6) R0670 Heterogeneity in susceptibility to co-morbidity
EIR 0.1a,1,2,4,8,16,64,256
Access to uncomplicated case management b (%) 0,5,40
Access inpatient care for severe cases c (%) 0,100 (for fitting 0,40,80)
Vaccination coverage d (%) 0,100
Initial efficacy against infection (%) 30,50,65,80,95 (for fitting 20,30,40,50,60,85)
Half-life (years) 1,2,5
Weibull decay shape parameter (k) k=1 (exponential)
  k=0.5 (bi-phasic)
  k=2 (slow decay, followed by quick decay)
  1. aEIR of 0.1 was not simulated, but any predictions for this level are taken as 10% of EIR 1
  2. bProbability of access to treatment for uncomplicated disease during a 5-day period
  3. cProbability of access to hospital care (or equivalent) for severe disease during any 5-day period
  4. dFor each of the four delivery schedules